ArticleScientific reports2025
Antifungal and fungicide susceptibility of clinical, animal, and environmental Fusarium and Neocosmospora species from Colombia: a one-health approach.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fusarium and Neocosmospora are widely recognized genera pathogenic to humans, animals, and plants. While the resistance of clinical and environmental strains to antifungal drugs and fungicide agents has been extensively studied, there is still limited knowledge regarding the susceptibility profiles within the One Health context. This study aims to investigate the susceptibility of clinical, animal, and environmental isolates collected during a One Health project conducted in Colombia from 2021 to 2023 to four antifungals i.e. amphotericin B, voriconazole, itraconazole, and posaconazole, as well as four fungicides, i.e. imazalil, propiconazole, tebuconazole, and difenoconazole. The results revealed that most clinical, animal, and environmental isolates were susceptible to amphotericin B and voriconazole. However, all tested isolates exhibited high Minimum Inhibitory Concentrations (MIC) for itraconazole, posaconazole, propiconazole, tebuconazole, and difenoconazole. These findings underscore the importance of initiating surveillance for antifungal and fungicide susceptibility within the framework of the One Health initiative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.